DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Early Phase 1

Withdrawn

Conditions: Cutaneous T Cell Lymphoma

Interventions: Drug: Durvalumab
Radiation: Radiation Therapy

First Posted Date: 2017-08-01

Last Posted Date: 2018-03-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT03235869

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pevonedistat
Drug: Docetaxel

First Posted Date: 2017-07-24

Last Posted Date: 2023-10-23

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT03228186

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Early Phase 1

Terminated

Conditions: Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Radium-223

First Posted Date: 2017-07-05

Last Posted Date: 2018-10-24

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 1

Registration Number: NCT03208712

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Palbociclib
Drug: Carboplatin

First Posted Date: 2017-06-21

Last Posted Date: 2021-04-12

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 21

Registration Number: NCT03194373

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma

Not Applicable

Withdrawn

Conditions: Carcinoma, Hepatocellular

Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT)
Radiation: Microwave Ablation (MWA)

First Posted Date: 2017-05-30

Last Posted Date: 2018-06-25

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT03168152

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Patient and Caregiver Participation Through an Educational Health Information Technology System ("BMT Roadmap") in the Context of Hematopoietic Cell Transplantation

Not Applicable

Completed

Conditions: Patients Undergoing Bone Marrow Transplant (BMT)

Interventions: Other: BMT Roadmap

First Posted Date: 2017-05-22

Last Posted Date: 2017-12-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT03161665

Locations: 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pertuzumab
Drug: Tocilizumab

First Posted Date: 2017-05-01

Last Posted Date: 2021-09-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 11

Registration Number: NCT03135171

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Yale University, New Haven, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Functional Imaging in Lung SBRT

Completed

Conditions: Lung Cancer

Interventions: Other: CT Scan
Other: Lung CT
Other: MRI
Other: Walk Test
Other: SGRQ
Other: Biological Sample Collection
Other: Toxicity
Other: Cardiac Assessment

First Posted Date: 2017-04-20

Last Posted Date: 2019-10-17

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 33

Registration Number: NCT03121300

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Early Imaging Biomarkers in NSCLC

Completed

Conditions: Thoracic Cancer

Interventions: Other: Imaging Biomarkers
Other: Pulmonary
Other: Imaging
Other: Specimen Collection

First Posted Date: 2017-04-20

Last Posted Date: 2019-08-26

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 23

Registration Number: NCT03121287

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Phase 2

Completed

Conditions: Biliary Tract Neoplasms

Interventions: Drug: Gemcitabine
Drug: Ipilimumab
Drug: Cisplatin
Drug: Nivolumab

First Posted Date: 2017-04-05

Last Posted Date: 2022-10-28

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 75

Registration Number: NCT03101566

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy